The meeting called for deepening the reform of the entire medicine and medical device regulation process to increase China's ...

Cytokinetics finds a new partner in Greater China for its potential blockbuster drug — it could be one of a handful of ...

Apollomics Inc., a late-stage clinical biopharmaceutical company, said its leukemia drug failed to pass trials in China, a ...

China is going to be brimming with foreign brands showcasing their goods next year. Consumer-goods expos will be running throughout the year for products including dining ware, cosmetics, food and ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

China’s aggressive drive to replace brand-name foreign drugs with dirt-cheap homegrown generics has already taken a toll on ...

Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. The new ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

The strength of evidence is solid, supported by the multicenter phase II trial design, which included a substantial number of patients across 23 centers in China. However, the single-arm study design ...

Despite changing lifestyles, tea remains China's favorite drink - making the country the world's largest producer, exporter, and consumer. The earliest credible record of tea drinking in China ...